EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of MEDI ASSIST HEALTHCARE SERVICES LIMITED ₹226, price ₹299, upside -24.3%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · IN · ISIN INE456Z01021

MA Broad data Sep 27, 2026

MEDI ASSIST HEALTHCARE SERVICES LIMITED

MEDIASSIST · NSE

Weak valuationQuality is weak on top of the rich price.

!Fair value ₹226.12 · Overvalued (−24.3%)
!Quality 47/100
✓Healthy Growth (revenue 5y +22.9 %/yr)
!Thin margins · 9.7% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (6/14)
!Moderate moat 51/100
!Weak on valuation: 1 out of 100
!Weak on dividend: 20 out of 100
Watch MEDI ASSIST HEALTHCARE SERVICES LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹692.90 ₹296.75 Fair Value ₹226.12 Jan 2024 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

32‑month range ₹296.75 – ₹692.90 · fair‑value band ₹122.51 – ₹281.58 · the ₹298.50 price screens above the ₹226.12 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow MEDI ASSIST HEALTHCARE SERVICES in your weekly email

Every Wednesday you see whether MEDI ASSIST HEALTHCARE SERVICES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medi Assist Healthcare Services Limited, together with its subsidiaries, provides third party administration services in India and internationally. The company offers business support, health management, consultancy, contact center support, and other allied services related to the healthcare and health insurance sector.

Show more

Medi Assist Healthcare Services Limited, together with its subsidiaries, provides third party administration services in India and internationally. The company offers business support, health management, consultancy, contact center support, and other allied services related to the healthcare and health insurance sector. It also provides; and policy administration services to governments to enable public health schemes. The company was incorporated in 2000 and is headquartered in Bengaluru, India.

Stock analysis

MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST) currently trades at ₹298.50, while our model-based Fair Value estimate is ₹226.12, 24.3% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹349.75 per share, and 8 of the 26 models we run sit above the ₹298.50 price.

Bear case: the Dividend Discount group reads lowest at ₹41.68, and 18 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: ₹122.51 (bear) to ₹281.58 (bull), the price of ₹298.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

MEDI ASSIST HEALTHCARE SERVICES LIMITED reported revenue of ₹9.0B in FY2025 versus ₹3.9B in FY2021, a compound +23.1%/yr. Reported net income was ₹879M in FY2025, compounding +8.2%/yr from FY2021.

Key figures

Market cap ₹28.1B (≈ $292M) · P/E ratio 24.6 · P/S ratio 2.39 · EPS (TTM) ₹12.15 · Dividend yield 1.0% · Net margin 9.7% · Return on equity 12.7% · Return on assets (EBIT) 10.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 48% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 16% fair-value upside, at −24%, MEDIASSIST screens richer than that median.

Fair Value models

Bear ₹122.51 Fair Value ₹226.12 Bull ₹281.58
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹12.15 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF ₹122.43 ₹170.34 ₹303.14 78
Growth DCF ₹115.84 ₹177.76 ₹284.74 77
Residual Income ₹89.83 ₹96.63 ₹109.89 76
All 26 models by family
DCF Models
FCF DCF ₹122.43 ₹170.34 ₹303.14 78
Owner Earnings ₹202.72 ₹387.07 ₹708.82 73
5Y Revenue Exit ₹129.48 ₹224.62 ₹414.37 69
5Y EBITDA Exit ₹202.60 ₹378.74 ₹709.30 71
5Y P/E Exit ₹170.87 ₹356.05 ₹599.81 68
10Y Revenue Exit ₹120.73 ₹235.13 ₹344.99 65
10Y EBITDA Exit ₹169.06 ₹358.74 ₹720.87 64
10Y P/E Exit ₹149.69 ₹305.09 ₹581.52 60
Earnings-Based
Graham-Dodd ₹80.00 ₹557.94 ₹782.98 63
Lynch FV ₹180.28 ₹257.54 ₹334.81 61
PEG = 1.0 ₹180.28 ₹257.54 ₹334.81 57
EPV ₹95.45 ₹105.51 ₹113.68 74
Dividend Discount
Gordon GGM ₹26.23 ₹43.94 ₹57.03 68
DDM Multi-Stage ₹26.23 ₹41.68 ₹47.27 67
Multiples
P/E Multiple ₹194.13 ₹258.84 ₹323.55 63
P/S Multiple ₹150.01 ₹200.01 ₹250.01 58
P/B Multiple ₹150.01 ₹200.01 ₹250.01 55
EV/EBIT ₹177.94 ₹233.40 ₹288.86 66
EV/EBITDA ₹256.98 ₹338.79 ₹420.60 67
EV/Revenue ₹130.31 ₹181.20 ₹232.09 54
Asset-Based
NCAV (Graham) ₹56.15 ₹75.24 ₹112.30 54
Growth DCF
Growth DCF ₹115.84 ₹177.76 ₹284.74 77
Rev-Margin DCF ₹129.48 ₹247.71 ₹428.78 70
Economic Profit
Residual Income ₹89.83 ₹96.63 ₹109.89 76
ROIC Compounder ₹95.45 ₹105.51 ₹115.47 72
Growth Earnings
Growth-Adj P/E ₹244.82 ₹349.75 ₹454.67 67

Open the full fair value analysis →

Notify me when MEDIASSIST reaches fair value

Put MEDIASSIST on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 48 · Market factors (momentum, volatility) 22

Profitability 39
Margins and returns on capital today
Quality Growth 41
Are margins and returns improving?
Cashflow 39
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 26
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 17
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 61
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+25.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+20.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.5%
Dividend (yield on the price)1.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 11%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+36.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +30.9% a year for the price and +5.6% for the forecasts.
Forecast 2026 (sales)+7.9%
Forecast 2027 (sales)+7.9%
Forecast 2028 (sales)+13.0%
Projected 2029 (sales)+11.5%
Projected 2030 (sales)+9.9%

MEDIASSIST screens overvalued: fair value 24% below the price. Compare with UnitedHealth Group →

Compare MEDI ASSIST HEALTHCARE SERVICES LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Plans” was too small, so the broader sector is used.)Health Care · 2382 stocks

Beats the sector median on 5/13 measures
Overall it trails its sector peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −24.2% · Below median
Profitability
Return on equity (TTM) 12.7% · Top 25%
Return on assets 4.8% · Above median
Net margin (TTM) 9.7% · Above median
Operating margin (TTM) 11.3% · Above median
Growth and dividend
Revenue growth 28.1% · Top 25%
Dividend yield (TTM) 1.0% · Below median

Valuation Multiplesvs Health Care median · lower = cheaper

P/E (TTM) 24.6× · Pricier than median
P/B 3.35× · Pricier than median
P/S (TTM) 3.10× · Pricier than median
P/FCF 53.9× · Priciest 25%
EV/EBITDA 15.6× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 6
FUTURE (revenue growth)100 · sector 24
PAST (return on equity)51 · sector 16
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)20 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
UnitedHealth Group UNH $367.08 $295.49 −20%
CVS Health Corporation CVS $85.69 $42.44 −50%
Elevance Health, Inc ELV $388.82 $465.08 +20%
The Cigna Group CI $271.83 $495.96 +82%
Humana Inc HUM $397.93 $146.91 −63%
Molina Healthcare, Inc MOH $189.10 $219.06 +16%
Oscar Health, Inc OSCR $29.60 $59.20 +100%
Progyny, Inc PGNY $25.19 $35.44 +41%
Alignment Healthcare, Inc ALHC $8.21 $7.45 −9%
Healthconn Corp 6665 17.00 TWD 13.18 TWD −22%

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "MEDI ASSIST HEALTHCARE SERVICES LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/MEDIASSIST

Frequently asked questions

Is MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹226.12 versus a price of ₹298.50, about −24% upside (overvalued).
What is the fair value of MEDIASSIST?
Our model-based fair value for MEDI ASSIST HEALTHCARE SERVICES LIMITED is ₹226.12 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹298.50.
What is the quality score of MEDIASSIST?
MEDI ASSIST HEALTHCARE SERVICES LIMITED has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
Our model-based price target is the fair value of ₹226.12 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario ₹122.51, optimistic scenario ₹281.58. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDI ASSIST HEALTHCARE SERVICES LIMITED stock forecast for 2026?
Our models put fair value at ₹226.12, about −24% upside versus a price of ₹298.50 (overvalued). Cautious scenario ₹122.51, optimistic scenario ₹281.58. The calculation is refreshed regularly with new filings.
What is the revenue of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
MEDI ASSIST HEALTHCARE SERVICES LIMITED reported trailing-twelve-month revenue of about ₹9.0B (latest available figure, as of Sep 27, 2026).
Does MEDI ASSIST HEALTHCARE SERVICES LIMITED pay a dividend?
MEDI ASSIST HEALTHCARE SERVICES LIMITED currently shows a dividend yield of about 1.00% relative to its recent price (as of Sep 27, 2026).
What growth is priced into MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
For today's price to be fair in a discounted-cash-flow model, MEDI ASSIST HEALTHCARE SERVICES LIMITED would have to grow free cash flow by +36.3 % per year for five years (discount rate 15.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.9 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of MEDIASSIST use?
Our models discount MEDI ASSIST HEALTHCARE SERVICES LIMITED at 15.9 %: a base by market capitalisation (micro), damped by beta 1.15, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MEDI ASSIST HEALTHCARE SERVICES LIMITED that is +36.3 % per year a year over ten years, using the same discount rate (15.9 %) and the same formula as our fair value.
How much growth has MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST) delivered so far?
Over the past 5 years revenue at MEDI ASSIST HEALTHCARE SERVICES LIMITED grew +22.9 % a year. The price currently implies +36.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into MEDI ASSIST HEALTHCARE SERVICES LIMITED (+36.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The free-cash-flow yield on the price is 2.41 %: that much free cash flow MEDI ASSIST HEALTHCARE SERVICES LIMITED produces per unit of market value. When it exceeds the discount rate of our models (15.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDI ASSIST HEALTHCARE SERVICES LIMITED it is ₹226.12 per share (as of Sep 27, 2026), against a price of ₹298.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is MEDI ASSIST HEALTHCARE SERVICES LIMITED stock overvalued or undervalued in 2026?
As of Sep 27, 2026, MEDIASSIST trades above its calculated fair value: price ₹298.50, fair value ₹226.12, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDIASSIST?
No. The price is what the market pays today (₹298.50); the fair value is what the company's own numbers justify (₹226.12). For MEDI ASSIST HEALTHCARE SERVICES LIMITED the two are ₹72.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDI ASSIST HEALTHCARE SERVICES LIMITED worth?
The market values MEDI ASSIST HEALTHCARE SERVICES LIMITED at about ₹28.1B (market capitalisation, as of Sep 27, 2026). Per share that is ₹298.50; our models calculate a fair value of ₹226.12 per share.
What do the bullish and bearish scenarios say about MEDIASSIST?
Our models span a range for MEDI ASSIST HEALTHCARE SERVICES LIMITED: cautious scenario ₹122.51, base ₹226.12, optimistic ₹281.58 per share (as of Sep 27, 2026, price ₹298.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDIASSIST?
MEDI ASSIST HEALTHCARE SERVICES LIMITED trades at a price-to-earnings ratio of 24.6 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹226.12 is built from several models across several years. Other multiples: P/B 3.4, P/S 3.1, EV/EBITDA 15.6.
How solid is the balance sheet of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
Balance-sheet figures for MEDI ASSIST HEALTHCARE SERVICES LIMITED (as of Sep 27, 2026): return on equity 12.7%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is MEDIASSIST from its 52-week high?
MEDI ASSIST HEALTHCARE SERVICES LIMITED trades at ₹298.50, about 48% below its 52-week high of ₹571.15 and 1% above the low of ₹296.75 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹226.12 is for.
Which stocks are comparable to MEDI ASSIST HEALTHCARE SERVICES LIMITED?
From the same area (Healthcare) we also value UnitedHealth Group, CVS Health Corporation, Elevance Health, Inc, The Cigna Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDI ASSIST HEALTHCARE SERVICES LIMITED stock attractive at the current price?
The data as of Sep 27, 2026: price ₹298.50, calculated fair value ₹226.12 (−24%), Quality Score 47/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDIASSIST calculated?
We run MEDI ASSIST HEALTHCARE SERVICES LIMITED through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹226.12, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. MEDI ASSIST HEALTHCARE SERVICES LIMITED itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The closing price on Oct 1, 2026 was ₹298.50. Our model-based fair value is ₹226.12, about −24% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDI ASSIST HEALTHCARE SERVICES LIMITED right now?
The price sits above even our optimistic bull case (₹281.58). The favourable scenario is already priced in. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹122.51 to ₹281.58) leaves room in how you read the outcome.

Key figures of MEDI ASSIST HEALTHCARE SERVICES LIMITED

How large is the market capitalisation of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The market capitalisation of MEDI ASSIST HEALTHCARE SERVICES LIMITED is ₹28.1B (≈ $292M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The price-to-sales ratio of MEDI ASSIST HEALTHCARE SERVICES LIMITED is 2.39 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
Earnings per share at MEDI ASSIST HEALTHCARE SERVICES LIMITED are ₹12.15 (price ÷ EPS = P/E 24.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The dividend yield of MEDI ASSIST HEALTHCARE SERVICES LIMITED is 1.0% (payout 24.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The net margin of MEDI ASSIST HEALTHCARE SERVICES LIMITED is 9.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The return on equity (ROE) of MEDI ASSIST HEALTHCARE SERVICES LIMITED is 12.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
On an EBIT basis the return on assets of MEDI ASSIST HEALTHCARE SERVICES LIMITED is 10.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
The operating margin of MEDI ASSIST HEALTHCARE SERVICES LIMITED is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
Revenue at MEDI ASSIST HEALTHCARE SERVICES LIMITED is growing +28.1% versus a year earlier (3y avg +21.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST)?
Earnings per share at MEDI ASSIST HEALTHCARE SERVICES LIMITED are growing +140% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does MEDI ASSIST HEALTHCARE SERVICES LIMITED (MEDIASSIST) hold?
MEDI ASSIST HEALTHCARE SERVICES LIMITED holds more cash than debt, ₹319M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch MEDI ASSIST HEALTHCARE SERVICES LIMITED in the live analysis

One click puts MEDI ASSIST HEALTHCARE SERVICES LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.